Mitomycin C in the bladder after ureteroscopy for UTUC
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether a medicine called mitomycin C given as a one-time bladder treatment right after ureteroscopy can reduce later recurrence (measured by urine test results and “IVR rate”). It may help people with non-spreading UTUC who are having endoscopic procedures and are planned for this standard add-on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have suspected or confirmed non-metastatic UTUC and be scheduled for ureteroscopy (for diagnosis or treatment)
- Plan to receive a one-time instillation of mitomycin C after the procedure
- Be able to sign informed consent (agree to join the study)
- During the procedure, there must be a way to take tissue samples for pathology/histology
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests putting a chemotherapy drug (mitomycin C) directly into the bladder and kidney tube after a diagnostic scope procedure for patients with a suspected upper tract urothelial cancer. It aims to see if this treatment is safe and helps prevent the cancer from coming back.
This study is testing whether giving a single dose of chemotherapy directly into the kidney and ureter right after a scope procedure helps prevent upper urinary tract tumors from coming back. It’s for people who are about to have a scope to diagnose or treat a suspected or known tumor in the upper urinary tract.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This Phase 3 trial studies whether using gemcitabine (a chemotherapy medicine) in the urinary tract better prevents cancer from coming back than using a simple water wash. It involves people with upper tract urothelial carcinoma who are having curative surgery to remove the affected ureter or kidney tube.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
Hear when a new Upper Urinary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.